MSN Laboratories

Riociguat Tablets are approved by the USFDA as a generic equivalent of Adempas Tablets in five strengths

As India moves into 2026, industry experts state that the next phase of growth in pharmaceuticals will depend on strengthening…

At the recently held PPL Conclave 2025 in Hyderabad, a panel discussion titled "Aligning Packaging Strategies with R&D"…

The eighth edition of the FDD Conclave organised by Express Pharma witnessed a very interesting panel discussion on Injectable…

The first panel discussion at FDD Conclave 2025 was on ‘Accelerating OSD innovation: From R&D to Market’. It set the tone for…

In today’s communication-driven world, where every interaction matters, the pharma industry is embracing conversations that build…

PPL Conclave 2025 witnessed several compelling panel discussions. One of them was on 'Patient-centric packaging: Safe, Smart,…

The collaboration aims to help their professionals keep pace with the rapid global pharmaceutical industry evolution and in…

MSN has launched the product under the brand name PosaOne as 100 mg Delayed-Release tablets and 300 mg injections, respectively

On May 10, Lilly had also announced the signing of three Voluntary License Agreements with Cipla, Lupin and Sun Pharma Industries